HC Wainwright Issues Pessimistic Outlook for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at HC Wainwright lowered their Q2 2025 earnings estimates for shares of United Therapeutics in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $7.02 per share for the quarter, down from their prior forecast of $7.39. HC Wainwright has a “Buy” rating and a $425.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.03 EPS and Q4 2025 earnings at $6.63 EPS.

A number of other research firms also recently commented on UTHR. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley upped their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research report on Thursday, May 1st. Wells Fargo & Company reissued an “equal weight” rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Finally, Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $392.00.

United Therapeutics Stock Down 1.2 %

UTHR opened at $295.02 on Tuesday. The stock has a market capitalization of $13.30 billion, a price-to-earnings ratio of 12.96, a PEG ratio of 0.97 and a beta of 0.58. The firm has a 50 day moving average price of $300.98 and a 200-day moving average price of $343.30. United Therapeutics has a twelve month low of $260.41 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $6.17 earnings per share.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics during the 4th quarter valued at approximately $25,000. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the last quarter. Sound Income Strategies LLC purchased a new position in shares of United Therapeutics in the first quarter valued at $49,000. State of Wyoming bought a new stake in United Therapeutics in the fourth quarter worth $62,000. Finally, Curat Global LLC purchased a new stake in United Therapeutics during the first quarter valued at $63,000. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $10,437,712.18. This trade represents a 23.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $956,195.85. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 75,500 shares of company stock valued at $24,245,880. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.